CD4+ T cell

Immune-Oncology Assays

  • Polyclonal
  • MLR
  • Antigen specificity
  • nTreg suppression assay
  • iTreg polarisation assay

Autoimmunity Assays

  • Th1/2/17 polarisation
  • Th17 function
  • Tr1/iTreg polarisation
  • nTreg suppression
  • Tfh, naïve
  • CM and EM phenotype/function
  • Polyclonal T cell proliferation
  • Cytokine release

Inflammation Assays

  • Cytokine release

Enzyme-Linked Immuno Spot (ELISpot) is a technique which quantifies immune cells of low abundance which release biomarkers such as cytokines in response to antigenic stimulation. ELISpot is a highly sensitive method to test immune modulators, novel vaccine candidates or de-risk immunogenicity testing in an antigen-specific CD4 and/or CD8 T cell assay.

ConditionAim
No StimulationNegative control
PMAPositive control
CERI
(CMV, EBV, RSV, Influenza)		MHC-I restricted peptide pool to evaluate modulation of CD8+ T-cell memory response
CPI
(CMV, Parainfluenza, Influenza)		Positive protein antigens to evaluate modulation of CD4+ T-cell memory response
CEF
(CMV, EBV, Influenza)		MHC-I restricted peptide pool to evaluate modulation of CD8+ T-cell memory response
Cyclosporin A (CsA)Inhibition of immune response
Figure 1: The ELISpot visual image results showing four donors under four conditions: Unstimulated (negative control), stimulated with PMA (positive control), stimulated with CERI, and stimulated with CPI antigens. Each purple spot represents one IFN-γ producing cell.

Spot Forming Units (SPU) for IFN-γ per 100,000 PBMC from CERI, CPI and CEF antigens for three donors

Figure 2: T cell responses from three donors using stimuli, CERI (I), CPI (II) and CEF (III).  Expressed as spot forming units per 100,000 donor PBMC. Depletion of CD4 or CD8 T cells demonstrates specificity of response to peptide pools. Each value represents the mean of triplicate wells ±SEM.

Evaluation of therapeutic modulation of Th17 differentiation

Figure 1: Polarisation of Th17 cells. Naïve CD4 cells were cultured under Th17 polarising conditions for 12 days in the presence or absence of Ursolic Acid. CD4 T cells were assessed for proliferation by CTV dilution; intracellular cytokine staining (ICS) of IL-17 and IL-10 by flow cytometry. On Day 12, Supernatants were collected and evaluated for IL-17 and IL-10 levels by MSD. Ursolic Acid showed selective inhibition of IL-17 production by ICS and MSD.

Evaluation of therapeutic modulation of antigen-specific memory T cell responses to recall antigens

I. T cell response to Tetanus Toxoid, Influenza and PPD antigens

II. Dose response to Influenza antigen

Antigen specific T cells response to a recall antigens. (I) Healthy donors PBMC were stimulated with PHA-M or triple antigen cocktail (Tetanus Toxoid, Influenza and PPD). Cyclosporin was used as a reference treatment. (II) Dose response to Influenza antigen. CD4 and CD8 T cells proliferation was measured by flow cytometry using CTV dilutions. 

Drug Discovery Tool

Find the right immune assay for your therapeutic area, modality and target using this interactive Drug Discovery Tool.

Explore now